XML 59 R48.htm IDEA: XBRL DOCUMENT v3.25.1
REVENUE AND SEGMENT INFORMATION - Significant expense categories (Details) - USD ($)
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
SEGMENT INFORMATION    
Total research and development $ 1,662,925 $ 2,246,911
Selling, general and administrative    
Stock-based compensation 818,426 959,465
Selling, general and administrative 8,431,880 9,283,067
Capital expenditures of the segment 47,242 127,018
Single reportable segment    
SEGMENT INFORMATION    
Clinical expenses 979,113 1,627,449
Other research and development expenses 683,812 619,462
Total research and development 1,662,925 2,246,911
Selling, general and administrative    
Royalty expense 257,883 712,385
Stock-based compensation 626,641 959,465
Legal, financial and other consulting 637,981 680,706
Other general and administrative 6,909,375 6,930,511
Selling, general and administrative $ 8,431,880 $ 9,283,067